Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
06 October 1995Website:
http://www.myriad.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 53 min agoDividend
Analysts recommendations
Institutional Ownership
MYGN Latest News
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025. After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverage of GeneSight.
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ:MYGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company's quarterly earnings will be released the same day after the market closes.
MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.
Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad's Precise® MRD test.
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad's ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco.
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
What type of business is Myriad Genetics?
Myriad Genetics, Inc. is one of the largest specialized molecular diagnostic laboratories in the world. Founded in 1992, the headquarters is located in Salt Lake City, Utah. The company uses a range of patented technologies, including DNA, RNA, and protein analysis, to help understand the genetic basis of human diseases and the role that genes and their associated proteins may play in the onset and progression of disease. The company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests designed to assess individual risk of developing disease in old age, determine the likelihood of a patient's response to drug therapy and dosage for the patient, or assess the risk of disease progression and recurrence.
What sector is Myriad Genetics in?
Myriad Genetics is in the Healthcare sector
What industry is Myriad Genetics in?
Myriad Genetics is in the Diagnostics & Research industry
What country is Myriad Genetics from?
Myriad Genetics is headquartered in United States
When did Myriad Genetics go public?
Myriad Genetics initial public offering (IPO) was on 06 October 1995
What is Myriad Genetics website?
https://www.myriad.com
Is Myriad Genetics in the S&P 500?
No, Myriad Genetics is not included in the S&P 500 index
Is Myriad Genetics in the NASDAQ 100?
No, Myriad Genetics is not included in the NASDAQ 100 index
Is Myriad Genetics in the Dow Jones?
No, Myriad Genetics is not included in the Dow Jones index
When was Myriad Genetics the previous earnings report?
No data
When does Myriad Genetics earnings report?
The next expected earnings date for Myriad Genetics is 07 November 2024